The recombinant bacteriophage endolysin HY-133 exhibits in vitro activity against different African clonal lineages of the staphylococcus aureus complex, including staphylococcus schweitzeri

Idelevich E., Schaumburg F., Knaack D., Scherzinger A., Mutter W., Peters G., Peschel A., Becker K.

Research article (journal) | Peer reviewed

Abstract

HY-133 is a recombinant bacteriophage endolysin with bactericidal activity against Staphylococcus aureus. Here, HY-133 showed in vitro activity against major African methicillin-susceptible and methicillin-resistant S. aureus lineages and ceftaroline/ceftobiprole-and borderline oxacillin-resistant isolates. HY-133 was also active against Staphylococcus schweitzeri, a recently described species of the S. aureus complex. The activity of HY-133 on the tested isolates (MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml; range, 0.125 to 0.5 μg/ml) was independent of the species and strain background or antibiotic resistance.

Details about the publication

JournalAntimicrobial Agents and Chemotherapy (Antimicrob Agents Chemother)
Volume60
Issue4
Page range2551-2553
StatusPublished
Release year2016
Language in which the publication is writtenEnglish
DOI10.1128/AAC.02859-15
Link to the full texthttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84963785986&origin=inward

Authors from the University of Münster

Becker, Karsten
Institute of Medical Microbiology
Idelevich, Evgeny
Institute of Medical Microbiology
Knaack, Dennis
Institute of Medical Microbiology
Peters, Georg
Institute of Medical Microbiology
Schaumburg, Frieder
Institute of Medical Microbiology